Evaluating utilization characteristics for the Oncotype DX recurrence score in early-stage breast cancer.

Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor–positive, human epidermal growth factor receptor 2–negative early-stage breast cancer

“…Indeed, when the intermediate Recurrence Score group was divided into those with 18e25 and 26e30 Recurrence Score results, CHT recommendation rate increased more pronouncedly in the latter subgroup (relative increase of 37% versus 25%). The present data are consistent with studies from the United States and Israel showing that decisions in patients with intermediate results are determined primarily based on whether the result is low or high (within the intermediate range) with a strong increase in chemotherapy recommendations in patients with scores >25 and that other traditional factors such as grade, tumour size, and age also matter [9,28,29]. Notably, results from the Clalit study [9] where patients were not randomized to chemotherapy or no chemotherapy indicate that patients with Recurrence Score results of 25 or less without other high-risk features have little or no benefit from chemotherapy, although it should be noted that the results of TAI-LORx on the role of chemotherapy in intermediate Recurrence Score patients are pending.…”